Premium
Syndrome of inappropriate antidiuretic hormone secretion. A complication of high‐dose intravenous melphalan
Author(s) -
GreenbaumLefkoe Barbara,
Rosenstock Jeffrey G.,
Belasco Jean B.,
Rohrbaugh Thomas M.,
Meadows Anna T.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850101)55:1<44::aid-cncr2820550107>3.0.co;2-b
Subject(s) - medicine , hyponatremia , melphalan , bolus (digestion) , complication , antidiuretic , syndrome of inappropriate antidiuretic hormone secretion , intravenous bolus , chemotherapy , urinary system , hormone , anesthesia , urology , surgery
Melphalan is now being investigated as an intravenous (IV) bolus chemotherapeutic agent in children with resistant tumors involving the bone marrow. Two patients received 2 mg/kg melphalan, IV bolus; 10 patients received 1 mg/kg. Seven of the ten patients receiving 1 mg/kg had noticeable downward trends in the serum sodium concentrations, whereas both patients receiving 2 mg/kg developed hyponatremia (serum sodium concentration [S Na ], mEq/1 = 124‐125) and inappropriate urinary sodium losses. Syndrome of inappropriate antidiuretic hormone (SiADH) is a previously unreported complication of high dose bolus melphalan therapy.